(WFRF:(Snowden John A.))
Sökning: (WFRF:(Snowden John A.)) > New autoimmune dise...
New autoimmune diseases after autologous hematopoietic stem cell transplantation for multiple sclerosis
-
- Burt, Richard K. (författare)
- Northwestern Univ, Dept Med, Div Immunotherapy, Feinberg Sch Med, Chicago, IL 60611 USA.
-
- Muraro, Paolo A. (författare)
- Imperial Coll London, Neuroimmunol & Immunotherapy, Dept Brain Sci, London, England.
-
- Farge, Dominique (författare)
- Univ Paris, Unite Med Interne Malad Autoimmunes & Pathol Vasc, Hop St Louis,AP HP,IRSL,MATHEC,EA 3518,Filiere FA, Ctr Reference Malad Autoimmunes Syst Rares Ile De, Paris, France.
- visa fler...
- visa färre...
- Northwestern Univ, Dept Med, Div Immunotherapy, Feinberg Sch Med, Chicago, IL 60611 USA Imperial Coll London, Neuroimmunol & Immunotherapy, Dept Brain Sci, London, England. (creator_code:org_t)
- 2021-04-28
- 2021
- Engelska.
- Ingår i: Bone Marrow Transplantation. - : Springer Nature. - 0268-3369 .- 1476-5365. ; 56:7, s. 1509-1517
- Forskningsöversikt (refereegranskat)
Abstract
Ämnesord
Stäng
- Secondary autoimmune diseases (2ndADs), most frequently autoimmune cytopenias (AICs), were first described after allogeneic hematopoietic stem cell transplantation (HSCT) undertaken for malignant and hematological indications, occurred at a prevalence of similar to 5-6.5%, and were attributed to allogeneic immune imbalances in the context of graft versus host disease, viral infections, and chronic immunosuppression. Subsequently, 2ndADs were reported to complicate roughly 2-14% of autologous HSCTs performed for an autoimmune disease. Alemtuzumab in the conditioning regimen has been identified as a risk for development of 2ndADs after either allogeneic or autologous HSCT and is consistent with the high rates of 2ndADs when using alemtuzumab as monotherapy. Due to the significant consequences but variable incidence, depending on conditioning regimen, of 2ndADs and similarity in known immune reconstitution kinetics after autologous HSCT for autoimmune diseases and after alemtuzumab monotherapy, we propose that an imbalance between B and T lineage regeneration early after HSCT may underlie the pathogenesis of 2ndADs.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- for (ämneskategori)
Hitta via bibliotek
- Bone Marrow Transplantation (Sök värdpublikationen i LIBRIS)
Till lärosätets databas
Hitta mer i SwePub
- Av författaren/redakt...
- Burt, Richard K.
- Muraro, Paolo A.
- Farge, Dominique
- Oliveira, Maria ...
- Snowden, John A.
- Saccardi, Riccar ...
- visa fler...
- Han, Xiaoqiang
- Quigley, Kathlee ...
- Bueno, Valquiria
- Frasca, Daniela
- Fedorenko, Denis
- Burman, Joachim, ...
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Hematologi
- Artiklar i publikationen
- Bone Marrow Tran ...
- Av lärosätet
- Uppsala universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
